论文部分内容阅读
目的评价诺和锐30治疗2型糖尿病的临床疗效。方法回顾分析95例患者的临床资料。结果本组95例患者的胰岛素用量逐渐减少,血糖控制良好而在治疗后3～6周后停用胰岛素;治疗3个月后,空腹血糖、餐后2h血糖、糖化血红蛋白与治疗前比较均有统计学意义(P<0.05),治疗期间4例发生轻度低血糖,经调整进餐及胰岛素用量后纠正,无严重低血糖发生;1例注射局部皮肤红肿和瘙痒,改变注射部位后缓解。结论诺和锐30治疗2型糖尿病安全有效,可明显改善患者的生存质量,值得临床应用。
Objective To evaluate the clinical efficacy of Novo Rui 30 in the treatment of type 2 diabetes mellitus. Methods The clinical data of 95 patients were retrospectively analyzed. Results The insulin dosage of 95 patients in this group decreased gradually and the blood sugar was well controlled. The insulin was stopped after 3 to 6 weeks after treatment. After 3 months of treatment, the fasting blood glucose, postprandial blood glucose 2h, HbA1c (P <0.05). During the treatment period, mild hypoglycemia occurred in 4 patients, corrected for meal and insulin dosage, and no serious hypoglycemia occurred. One patient was infiltrated and pruritus on the local skin, which was relieved after the injection site was changed. Conclusion Novo Rui 30 treatment of type 2 diabetes is safe and effective, can significantly improve the quality of life of patients, it is worth clinical application.